Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Adoptive cancer immunotherapy using DNA-demethylated T helper cells as antigen-presenting cells

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. An atlas of O-linked glycosylation on peptide hormones reveals diverse biological roles

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. A phenome-wide association and Mendelian Randomisation study of polygenic risk for depression in UK Biobank

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Author Correction: Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. SUCLA2 mutations cause global protein succinylation contributing to the pathomechanism of a hereditary mitochondrial disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. PET imaging of meningioma with 18F-FLT: a predictor of tumour progression

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Effect of blood glucose and body weight on image quality in brain [18F]FDG PET imaging

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Mitotic and Proliferative Indices in WHO Grade III Meningioma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

In cancer cells, cancer/testis (CT) antigens become epigenetically derepressed through DNA demethylation and constitute attractive targets for cancer immunotherapy. Here we report that activated CD4+ T helper cells treated with a DNA-demethylating agent express a broad repertoire of endogenous CT antigens and can be used as antigen-presenting cells to generate autologous cytotoxic T lymphocytes (CTLs) and natural killer cells. In vitro, activated CTLs induce HLA-restricted lysis of tumor cells of different histological types, as well as cells expressing single CT antigens. In a phase 1 trial of 25 patients with recurrent glioblastoma multiforme, cytotoxic lymphocytes homed to the tumor, with tumor regression ongoing in three patients for 14, 22, and 27 months, respectively. No treatment-related adverse effects were observed. This proof-of-principle study shows that tumor-reactive effector cells can be generated ex vivo by exposure to antigens induced by DNA demethylation, providing a novel, minimally invasive therapeutic strategy for treating cancer.

OriginalsprogEngelsk
TidsskriftNature Communications
Vol/bind9
Udgave nummer1
Sider (fra-til)785
ISSN2041-1723
DOI
StatusUdgivet - 6 mar. 2018

ID: 55350890